Lumida
/BEAM
⌘K
Beam Therapeutics Inc

Beam Therapeutics Inc

BEAM
$27.53USD↓-3.03%-0.86 today

MARKET CAP

2.8B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$27 – $29

52W RANGE

$16
$38

AI Summary

Stalk
TrimMedium

BEAM remains in a Stage 4 decline with a confirmed lower-high, lower-low sequence and active Bearish Exhaustion, sustaining a bearish medium-term bias. Price is extended below the declining 9, 21, and 50 EMAs and is extreme oversold, delaying immediate sell entries. Under a speculative framework, sell interactions should be deferred until pullbacks into the EMA or prior support zones for rejection. The long-term uptrend remains intact but faces risk if price breaks below the 200 DMA.

  • ↑Beam 101 trial boosted hemoglobin from 9.3 to 17.9 g/dL in early data.
  • ↑Q4’25 cash of $1.25B and Sixth Street financing extend runway into 2029.
  • ↓Earnings yield at -3.09 and profitability score at -2.49 indicate persistent unprofitability.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Beam Therapeutics (NASDAQ: BEAM) is an emerging biotechnology company specializing in precision genetic medicine, primarily focusing on developing innovative treatments for genetic disorders via its proprietary base editing technology. This unique approach enables precise genetic modifications without double-stranded DNA breaks, positioning Beam at the forefront of groundbreaking therapies for severe diseases, particularly sickle cell disease and phenylketonuria (PKU). With a strengthened clinical pipeline, Beam aims to address critical unmet needs within hematology and liver disease sectors.

Bull says

  • ↑Beam 101 trial boosted hemoglobin from 9.3 to 17.9 g/dL in early data.
  • ↑Q4’25 cash of $1.25B and Sixth Street financing extend runway into 2029.
  • ↑Revision gains and 13F ownership reflect rising analyst and institutional confidence.
  • ↑Beam 304 IND slated for 2026 addresses ~20,000 US PKU patients.
  • ↑Proprietary ESCAPE editing could outpace chemo-based transplant methods in gene therapies.

Bear says

  • ↓Earnings yield at -3.09 and profitability score at -2.49 indicate persistent unprofitability.
  • ↓Q4’25 operating margin of -226.6% and P/E of -49 signal overvaluation.
  • ↓Busulfan-related patient death highlights safety and regulatory enforcement risks.
  • ↓Prime Medicine arbitration threatens IP around AATD program, intensifying competition.
  • ↓Shares down 19% over six days amid fears of shrinking returns.
  • ↓High volatility and short interest reflect elevated price instability and bearish sentiment.

Investment themes with BEAM

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q3 2024 · Mgmt. Guidance

Updated 07-17-2026bullish

Transcript signals

Bull points

  • to date, we've exceeded enrollment projections with 35 patients having cleared screening and enrolled in the study.
  • Beam 101 was considered generally well tolerated and demonstrated a safety profile consistent with myeloblative conditioning with Busulfan and autologous hematopoietic stem cell transplant.
  • Rapid neutrophil engraftment was observed for all patients after Beam 101 treatment with a median of 17 days and a range of 15 to 19 days.

Bear points

  • one patient died due to respiratory failure four months after their Beam 101 infusion, which was determined by the investigator to be likely related to Busulfan conditioning.
  • unfortunate death attributed to gasolping, but it was determined that the safety profile of the study had not changed after this event.
Read full transcript analysis ›